| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
AUTOANTIBODIES BY MULTIPLEX FLOW IMMUNOASSAY w/ AUTO DISPLAY OF ANTIGENS
MessageANA will automatically include panel regardless of screening result.
Test Code
ANBSP
Alias/See Also
Antinuclear;ANA
CPT Codes
86038; 86235 x10; 86225
Includes
Includes: Quantitative detection of dsDNA, semi-quantitative detection of Chromatin, Ribosomal P, SS-A, SS-B, Sm, SmRNP, RNP, Scl-70, Jo-1, and Centromere B
Preferred Specimen
1 Gold tube (gel separator)
Minimum Volume
0.5 mL
Other Acceptable Specimens
or 1 Lavender tube (EDTA)
or 1 Green tube (Lithium heparin)
or 1 Green tube (Lithium heparin)
Instructions
Centrifuge for complete separation of plasma or serum and red cells. Separate and refigerate until tested.
Transport Temperature
Refrigerate
Specimen Stability
- 2-8°C up to 7 days otherwise freeze at -20°C or lower
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolyzed or lipemic samples will be rejected
Methodology
Multiplex Flow Immunoassay
Setup Schedule
M, Tu, W, Th, F, Sa, Su
Report Available
​Report available within 24 hours of receipt at the performing laboratory.
Reference Range
Negative
Clinical Significance
This test utilizes a multiplex bead assay to assess the presence of antibodies associated with systemic autoimmune diseases which may be helpful in the diagnosis of Rheumatoid arthritis (RA), Systemic Lupus Erythematosus, Scleroderma, Mixed Connective Tissue disease, Undifferentiated Connective Tissue disease, Sjogren&rsquo s syndrome, Dermatomyositis, Polymyositis, and Raynaud&rsquo s phenonmenon.
The test quantitatively detects dsDNA and qualitatively detects Chromatin, Ribosomal P, SS-A 60, SS-A 52, SS-B, Sm, SmRNP, RNP A, RNP 68, Scl-70, Jo-1 and Centromere B. Proprietary software is used to report an association between the antibodies detected and systemic autoimmune disease.
The test is intended for diagnostic use and is of limited clinical utility in monitoring disease course. Overlap may occur between antibodies and diseases. If a negative result is obtained in the presence of clinical signs and symptoms suggestive of systemic autoimmune disease, repeat testing using an alternative method is suggested (IFA). Positive results can be seen in apparently healthy individuals stressing the importance of clinical correlation with patient signs and symptoms. Patients with RA may demonstrate positivity in the assay with dsDNA and Chromatin.
The test quantitatively detects dsDNA and qualitatively detects Chromatin, Ribosomal P, SS-A 60, SS-A 52, SS-B, Sm, SmRNP, RNP A, RNP 68, Scl-70, Jo-1 and Centromere B. Proprietary software is used to report an association between the antibodies detected and systemic autoimmune disease.
The test is intended for diagnostic use and is of limited clinical utility in monitoring disease course. Overlap may occur between antibodies and diseases. If a negative result is obtained in the presence of clinical signs and symptoms suggestive of systemic autoimmune disease, repeat testing using an alternative method is suggested (IFA). Positive results can be seen in apparently healthy individuals stressing the importance of clinical correlation with patient signs and symptoms. Patients with RA may demonstrate positivity in the assay with dsDNA and Chromatin.
Performed By
Alverno Laboratories
Performing Laboratory
Alverno Central Lab
NIM5 (Immunology, Bioplex)
Last Updated: June 8, 2023
